Summary of Study ST004185

This data is available at the NIH Common Fund's National Metabolomics Data Repository (NMDR) website, the Metabolomics Workbench, https://www.metabolomicsworkbench.org, where it has been assigned Project ID PR002640. The data can be accessed directly via it's Project DOI: 10.21228/M8DC3J This work is supported by NIH grant, U2C- DK119886.

See: https://www.metabolomicsworkbench.org/about/howtocite.php

This study contains a large results data set and is not available in the mwTab file. It is only available for download via FTP as data file(s) here.

Show all samples  |  Perform analysis on untargeted data  
Download mwTab file (text)   |  Download mwTab file(JSON)   |  Download data files (Contains raw data)
Study IDST004185
Study TitleMaternal and fetal Tryptophan-Kynurenine metabolite changes in Preeclampsia and Gestational Diabetes
Study TypeMetabolomics
Study SummaryPreeclampsia (PE) and gestational diabetes mellitus (GDM) are major pregnancy complications associated with maternal and neonatal morbidity, including fetal growth restriction and preterm birth. Both disorders involve systemic metabolic dysregulation; however, their effects on maternal and neonatal metabolomic profiles, especially in the Indian population, remain underexplored. In this prospective cohort study, maternal serum and neonatal cord blood were analyzed using ultra-high performance liquid chromatography coupled with Orbitrap mass spectrometry. Differential metabolites were identified and subjected to pathway enrichment and correlation analysis with clinical traits. Distinct metabolomic alterations were observed in maternal and neonatal samples from PE and GDM groups, with notable overlap in neonatal profiles despite differing maternal conditions. Dysregulation of tryptophan–kynurenine (TRP–KYN) pathway metabolites, including kynurenine, quinolinic acid, and serotonin, emerged in both groups and correlated with gestational age, placental weight, vitamin D status, and neonatal bone mineral density. Pathway analysis further highlighted disruptions across multiple metabolic pathways. These findings demonstrate metabolic perturbations in PE and GDM, underscoring the TRP–KYN pathway as a shared feature influencing fetal development. This pathway may serve as a biomarker and therapeutic target, warranting validation in larger cohorts and deeper molecular investigation.
Institute
Translational Health Science And Technology Institute (THSTI)
DepartmentNCD
LaboratoryBiomarker lab
Last NameKumar
First NameYashwant
AddressNCR Biotech Science Cluster,, Faridabad, Haryana, 121001, India
Emaily.kumar@thsti.res.in
Phone+911292876496
Submit Date2025-09-08
Raw Data AvailableYes
Raw Data File Type(s)mzML, raw(Thermo)
Analysis Type DetailLC-MS
Release Date2025-10-06
Release Version1
Yashwant Kumar Yashwant Kumar
https://dx.doi.org/10.21228/M8DC3J
ftp://www.metabolomicsworkbench.org/Studies/ application/zip

Select appropriate tab below to view additional metadata details:

Project:

Project ID:PR002640
Project DOI:doi: 10.21228/M8DC3J
Project Title:Maternal and fetal Tryptophan-Kynurenine metabolite changes in Preeclampsia and Gestational Diabetes
Project Type:Metabolomics
Project Summary:Preeclampsia (PE) and gestational diabetes mellitus (GDM) are major pregnancy complications associated with maternal and neonatal morbidity, including fetal growth restriction and preterm birth. Both disorders involve systemic metabolic dysregulation; however, their effects on maternal and neonatal metabolomic profiles, especially in the Indian population, remain underexplored. In this prospective cohort study, maternal serum and neonatal cord blood were analyzed using ultra-high performance liquid chromatography coupled with Orbitrap mass spectrometry. Differential metabolites were identified and subjected to pathway enrichment and correlation analysis with clinical traits. Distinct metabolomic alterations were observed in maternal and neonatal samples from PE and GDM groups, with notable overlap in neonatal profiles despite differing maternal conditions. Dysregulation of tryptophan–kynurenine (TRP–KYN) pathway metabolites, including kynurenine, quinolinic acid, and serotonin, emerged in both groups and correlated with gestational age, placental weight, vitamin D status, and neonatal bone mineral density. Pathway analysis further highlighted disruptions across multiple metabolic pathways. These findings demonstrate metabolic perturbations in PE and GDM, underscoring the TRP–KYN pathway as a shared feature influencing fetal development. This pathway may serve as a biomarker and therapeutic target, warranting validation in larger cohorts and deeper molecular investigation.
Institute:Translational Health Science And Technology Institute (THSTI)
Department:NCD
Laboratory:Biomarker lab
Last Name:Kumar
First Name:Yashwant
Address:NCR Biotech Science Cluster,, Faridabad, Haryana, 121001, India
Email:y.kumar@thsti.res.in
Phone:01292876496
Funding Source:THSTI

Subject:

Subject ID:SU004337
Subject Type:Human
Subject Species:Homo sapiens
Taxonomy ID:9606

Factors:

Subject type: Human; Subject species: Homo sapiens (Factor headings shown in green)

mb_sample_id local_sample_id Sample source Group
SA482960CB_1Serum control baby
SA482961CB_10Serum control baby
SA482962CB_3Serum control baby
SA482963CB_4Serum control baby
SA482964CB_5Serum control baby
SA482965CB_6Serum control baby
SA482966CB_7Serum control baby
SA482967CB_8Serum control baby
SA482968CB_2Serum control baby
SA482969CB_9Serum control baby
SA482970CM_9Serum control mother
SA482971CM_10Serum control mother
SA482972CM_1Serum control mother
SA482973CM_3Serum control mother
SA482974CM_4Serum control mother
SA482975CM_5Serum control mother
SA482976CM_6Serum control mother
SA482977CM_7Serum control mother
SA482978CM_8Serum control mother
SA482979CM_2Serum control mother
SA482940GB_10Serum Gestational baby
SA482941GB_3Serum Gestational baby
SA482942GB_4Serum Gestational baby
SA482943GB_5Serum Gestational baby
SA482944GB_6Serum Gestational baby
SA482945GB_7Serum Gestational baby
SA482946GB_8Serum Gestational baby
SA482947GB_9Serum Gestational baby
SA482948GB_2Serum Gestational baby
SA482949GB_1Serum Gestational baby
SA482950GM_3Serum Gestational mother
SA482951GM_4Serum Gestational mother
SA482952GM_5Serum Gestational mother
SA482953GM_6Serum Gestational mother
SA482954GM_7Serum Gestational mother
SA482955GM_8Serum Gestational mother
SA482956GM_9Serum Gestational mother
SA482957GM_10Serum Gestational mother
SA482958GM_2Serum Gestational mother
SA482959GM_1Serum Gestational mother
SA482980PB_7Serum preaclamsia baby
SA482981PB_10Serum preaclamsia baby
SA482982PB_9Serum preaclamsia baby
SA482983PB_8Serum preaclamsia baby
SA482984PB_6Serum preaclamsia baby
SA482985PB_5Serum preaclamsia baby
SA482986PB_4Serum preaclamsia baby
SA482987PB_3Serum preaclamsia baby
SA482988PB_1Serum preaclamsia baby
SA482989PB_2Serum preaclamsia baby
SA482990PM_1Serum preaclamsia mother
SA482991PM_2Serum preaclamsia mother
SA482992PM_3Serum preaclamsia mother
SA482993PM_4Serum preaclamsia mother
SA482994PM_5Serum preaclamsia mother
SA482995PM_6Serum preaclamsia mother
SA482996PM_7Serum preaclamsia mother
SA482997PM_8Serum preaclamsia mother
SA482998PM_9Serum preaclamsia mother
SA482999PM_10Serum preaclamsia mother
Showing results 1 to 60 of 60

Collection:

Collection ID:CO004330
Collection Summary:Study Population and data collection: This prospective cohort study was conducted at the Department of Obstetrics and Gynaecology, All India Institute of Medical Sciences (AIIMS), New Delhi. Study subjects were enrolled from the antenatal clinic from January 2016 to June 2018. GDM cases were diagnosed on basis of the International Association of Diabetes and Pregnancy Study Groups (IADPSG) (3) criteria requiring at least one abnormal value from a 75g OGTT, showing fasting glucose ≥92 mg/dL, 1-hour glucose ≥180 mg/dL, or 2-hour glucose ≥153 mg/dL. Diagnosis of PE was according to the criteria of the International Society for the Study of Hypertension in Pregnancy (ISSHP) (9) on blood pressure >140/90 mm/Hg with at least two separate readings after 20 weeks of gestation with proteinuria >300 mg/24-h urine or >1+ in dipstick. All included subjects carried a singleton pregnancy. Any subject with pre-pregnancy diabetes mellitus, untreated hypo/ hyperthyroidism, chronic liver/renal disease, or any systemic illness was excluded from the study. Similarly, pregnancies with congenital malformations in fetuses were also excluded. After a detailed history and tailored clinical examination, blood samples from mothers were collected while they were admitted for delivery and cord blood samples were collected during delivery. Placental weight was measured by a standardized tabletop digital weighing scale. Informed written consent was secured from all participants, and ethical approval was obtained from the Institutional Ethics Committee of All India Institute of Medical Sciences-New Delhi (IEC/414/8/2016). Sample Collection and Neonatal Assessment After a detailed history and tailored clinical examination, blood samples from mothers were collected while they were admitted for delivery and cord blood samples were collected during delivery. Placental weight was measured by a standardized tabletop digital weighing scale and stored at -80°C for subsequent analysis. Serum was separated by centrifugation at 3,000 rpm for 10 minutes, aliquoted and stored at -80°C until analysis. After milk-feed, neonates were swaddled in a soft, warm cloth and placed on the platform in the supine position without sedation. DXA scans were performed within 48 h of birth by Hologic Discovery A 84023, QDR, USA scanner using pediatric software (Apex System software, version 4.5.2.1) to assess bone mineral content and body composition.
Sample Type:Blood (serum)

Treatment:

Treatment ID:TR004346
Treatment Summary:NA

Sample Preparation:

Sampleprep ID:SP004343
Sampleprep Summary:The serum samples were thawed on ice, and 50 µl was aliquoted for metabolite extraction. 100% chilled LC-MS grade Methanol (Honeywell 34966) was added in a 1:3 (v/v) ratio to each sample. The suspension was thoroughly mixed by brief vortexing and incubated on ice for 10 minutes. The samples were then centrifuged at 12,000rpm for 10 mins at 4° and the supernatant was carefully transferred in equal volumes, in two fresh MCTs. The methanol extract was evaporated using the speed vac sample concentrator at room temperature, followed by storage in a -80℃ freezer till further analysis. For injection into the LC-MS, the samples were reconstituted in 60 µl of 15% Methanol: water.

Chromatography:

Chromatography ID:CH005275
Chromatography Summary:The extracted serum metabolites were separated on Thermo UPLC Ultimate 3000. ACQUITY HSS T3 (2.1mm x100mm x1.8µm, Waters) column was used for metabolite separation. RPC Solvent A was 99.9% LC-MS grade water (Honeywell 39253) and 0.1% of LC-MS grade Formic acid (FA) (Fisher Chemical A117) and Solvent B was 99.9% LC-MS grade Methanol with 0.1% FA. The 14min elution gradient with a flow rate of 300 µl/min, started from 0.1%B to 15% B for 1min; 15%B to 35% for 4min; 35%B to 95%B for 3mins; maintained at 95% for 2mins and brought back to original 1%B over 4mins.
Instrument Name:Thermo Dionex Ultimate 3000
Column Name:Waters ACQUITY UPLC HSS T3 (100 x 2.1mm,1.8um)
Column Temperature:40°C
Flow Gradient:Started from 0.1%B to 15% B for 1min; 15%B to 35% for 4min; 35%B to 95%B for 3mins; maintained at 95% for 2mins and brought back to original 1%B over 4mins.
Flow Rate:300 ul/min
Solvent A:100% Water; 0.1% formic acid
Solvent B:100% Methanol; 0.1% formic acid
Chromatography Type:Reversed phase

Analysis:

Analysis ID:AN006949
Analysis Type:MS
Chromatography ID:CH005275
Has Mz:1
Has Rt:1
Rt Units:Minutes
Results File:ST004185_AN006949_Results.txt
Units:relative intensity
  
Analysis ID:AN006950
Analysis Type:MS
Chromatography ID:CH005275
Has Mz:1
Has Rt:1
Rt Units:Minutes
Results File:ST004185_AN006950_Results.txt
Units:relative intensity
  logo